Skip to Main content Skip to Navigation
Journal articles

Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax

Abstract : Since the discovery of apoptosis as a form of programmed cell death, targeting the apoptosis pathway to induce cancer cell death has been a high-priority goal for cancer therapy. After decades of effort, drug-discovery scientists have succeeded in generating small-molecule inhibitors of antiapoptotic BCL2 family proteins. Innovative medicinal chemistry and structure-based drug design, coupled with a strong fundamental understanding of BCL2 biology, were essential to the development of BH3 mimetics such as the BCL2-selective inhibitor venetoclax. We review a number of preclinical studies that have deepened our understanding of BCL2 biology and facilitated the clinical development of venetoclax. Significance: Basic research into the pathways governing programmed cell death have paved the way for the discovery of apoptosis-inducing agents such as venetoclax, a BCL2-selective inhibitor that was recently approved by the FDA and the European Medicines Agency. Preclinical studies aimed at identifying BCL2-dependent tumor types have translated well into the clinic thus far and will likely continue to inform the clinical development of venetoclax and other BCL2 family inhibitors. Cancer Discov; 7(12);
Document type :
Journal articles
Complete list of metadatas

Cited literature [130 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01638832
Contributor : Elizabeth Bernardo <>
Submitted on : Monday, November 20, 2017 - 11:33:32 AM
Last modification on : Thursday, June 18, 2020 - 10:32:02 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Joel Leverson, Deepak Sampath, Andrew Souers, Saul Rosenberg, Wayne Fairbrother, et al.. Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax. Cancer Discovery, American Association for Cancer Research, 2017, Epub ahead of print. ⟨10.1158/2159-8290.CD-17-0797⟩. ⟨inserm-01638832⟩

Share

Metrics

Record views

170